[221 Pages Report] Revenue from the global cytomegalovirus treatment market currently stands at US$ 228.8 Million in 2022. Rising at a CAGR of 6.1% (2022 to 2028), demand for cytomegalovirus treatment is predicted to reach a market valuation of US$ 326 Million by the end of 2028.
| Attribute | Details |
|---|---|
| Global Cytomegalovirus Treatment Market Size (2022) | US$ 228.8 Million |
| Net Revenue Estimation (2028) | US$ 326 Million |
| Global Growth Rate (2022 to 2028) | 6.1% CAGR |
| Market Share of Hospital Pharmacies | 47.8% |
Cytomegalovirus treatment contributes 0.8% to the global infectious disease diagnostics market revenue. Increasing instances of viral infections and rising awareness of cytomegalovirus symptoms are expected to propel demand for cytomegalovirus treatment on a global level.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
| Particulars | Details |
|---|---|
| H1, 2021 | 6.10% |
| H1, 2022 Projected | 6.08% |
| H1, 2022 Outlook | 5.48% |
| BPS Change - H1, 2022 (O) - H1, 2022 (P) | (-) 60 ↓ |
| BPS Change - H1, 2022 (O) - H1, 2021 | (-) 62 ↓ |
The comparative analysis and market growth rate of global cytomegalovirus treatment market as studied by Future Market Insights, will show a negative BPS growth in H1-2022 outlook as compared to H1-2022 projected period by 60 BPS. A decline in BPS growth is expected in H1-2022 over H1- 2021 duration with 62 Basis Point Share (BPS).
The market for cytomegalovirus treatment is subject to changes as per the macro and industrial standards in relevance to stringent regulations in biopharmaceuticals development and production and licensing.
The market observes a decline in the BPS values owed to the inefficacy of the therapy in patients with severe immunosuppression or disseminated disease. With the rising cases of such incidences after the global coronavirus pandemic, the limitations for cytomegalovirus treatment posed a negative impact upon the market growth, thus resulting in the dropped BPS values.
Conversely, with the recent FDA approval of the first drug for adults and paediatric patients with cytomegalovirus infections and diseases which cannot be managed with the current available antiviral treatment methods in 2022, has paved way for the market to observe a positive outlook towards growth over the forecasted years.
The key development in the market includes the adoption of oral antivirals such as ganciclovir for the management of cytomegalovirus in immunocompromised patients.
The world has seen substantial rise in viral infections and other infectious diseases, and this has propelled demand for better diagnostic and treatment solutions. The cytomegalovirus treatment market exhibited expansion at a CAGR of 5.7% from 2013 to 2021.
Increasing prevalence of congenital CMV infections, rising awareness about cytomegalovirus symptoms, increasing spending on research & development activities, rising clinical trials and studies for CMV infections, etc., are major trends that will guide cytomegalovirus treatment demand through 2028.
The risk of reactivation of cytomegalovirus infections in multiple individuals has been observed and this is one of the areas of prime focus for many cytomegalovirus treatment providers. The use of antiviral agents that have very low risks associated with them is seeing high demand in the development of antiviral drugs for cytomegalovirus diseases. Antiviral agents such as ganciclovir and valganciclovir are expected to see a rise in popularity over the forecast period.
Risks and side effects associated with antiviral drugs for cytomegalovirus diseases are anticipated to restrain market potential to a certain extent over the forecast period. The cytomegalovirus treatment industry is projected to rise at a steady CAGR of 6.1% from 2022 to 2028.
“Increasing Focus on Development of CMV Vaccines”
Awareness of cytomegalovirus symptoms is being raised across the world by multiple initiatives taken by governments and non-profit organizations to bolster public safety. Clinical trials are being carried out to boost the development of novel cytomegalovirus treatment.
“Risks of Antiviral Drugs for Cytomegalovirus Diseases Could Adversely Impact Market Growth”
Very little is known about CMV infections, and this has proven to be a major obstacle to cytomegalovirus diagnosis and cytomegalovirus testing. Increasing demand for cytomegalovirus natural treatment is also expected to constrain the adoption of antiviral drugs for cytomegalovirus diseases.
These factors are expected to have a hindering effect on global cytomegalovirus treatment device demand through 2028.
Principal Consultant
“High R&D Activity in North America to Boost Cytomegalovirus Diagnosis”
Detailed assessment of market stance across regions such as North America, Latin America, Europe, East Asia, South Asia & Pacific, and the Middle East & Africa (MEA) has been profiled in this revised FMI market analysis.
Demand for cytomegalovirus treatment products in North America is anticipated to hold a major market share in the global marketplace over the forecast. The presence of major cytomegalovirus treatment providers and rapid advancements in cytomegalovirus diagnosis and cytomegalovirus treatment are expected to shape market potential.
Rising prevalence of congenital CMV infections, increasing use of combinational antiviral therapies, and increasing awareness of cytomegalovirus treatment in stem cell transplants are expected to be major trends in the Europe cytomegalovirus treatment market over the forecast period.
Increasing investments in research & development activities, rising healthcare expenditure, and increasing popularity of cytomegalovirus natural treatment are major factors that influence cytomegalovirus treatment demand in South Asia and East Asia. Rising focus on boosting cytomegalovirus testing in these regions is expected to majorly favour market potential.
“Increasing Focus on Healthcare & Rising Awareness about Cytomegalovirus Symptoms in India”
The healthcare infrastructure in India is rapidly changing and the focus on health and hygiene has fostered a new wave of demand for better diagnostic and treatment solutions in the nation. Government initiatives are boosting awareness about viral infections and are further bolstering awareness about cytomegalovirus symptoms in India.
High population, increasing prevalence of HIV infections, high birthrate, etc., are some of the major factors that influence cytomegalovirus treatment market potential in India. Cytomegalovirus diagnosis and cytomegalovirus testing are expected to increase in India as awareness about cytomegalovirus symptoms increases through 2028.
“High Research Activity to Explore Cytomegalovirus Pathology to Boost Market Potential”
The U.S. is known for its well-established healthcare infrastructure, and this has made it a highly lucrative market for the healthcare industry. Cytomegalovirus treatment providers are expected to further advance their research & development activities to provide better cytomegalovirus diagnosis and treatment.
Rising research for cytomegalovirus testing, increasing investments from government and non-profit research organizations, and rising availability of cytomegalovirus diagnosis procedures are expected to be major factors influencing cytomegalovirus treatment market potential through 2028.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
“Hospital Pharmacies to Hold Dominant Market Share”
In 2022, hospital pharmacies account for 46.8% of the global cytomegalovirus treatment industry landscape. With most cytomegalovirus diagnosis procedures being accessible only through professional subscriptions, this has boosted their sales via hospital pharmacies, which are more accessible to patients and are recommended by professionals.
Other distribution channels such as retail pharmacies and e-Commerce currently hold market shares of 36.7% and 16.4%, respectively, in 2022, in the global cytomegalovirus treatment space.
In 2020, the healthcare industry was revolutionized by the emergence of coronavirus infections and adversely affected multiple treatment and diagnostic procedures across the world. As lockdown restrictions were imposed and outdoor activity was largely restricted, this led to a substantial drop in the research and development activities related to cytomegalovirus treatment.
Demand for cytomegalovirus treatment also experienced a drop during the pandemic era as all healthcare resources and professionals were focused on the treatment of coronavirus infections. However, the cytomegalovirus treatment market is predicted to make a steady comeback in the post-pandemic era as infections subside and the world returns to a new normal.
Cytomegalovirus treatment providers are investing in the research & development of innovative and more effective treatments for CMV infections.
| Attribute | Details |
|---|---|
| Forecast Period | 2022 to 2028 |
| Historical Data Available for | 2013 to 2021 |
| Market Analysis | US$ Mn for Value |
| Key Regions Covered |
|
| Key Countries Covered |
|
| Key Market Segments Covered |
|
| Key Companies Profiled |
|
| Pricing | Available upon Request |
Cytomegalovirus Treatment Market by Drug Type:
Cytomegalovirus Treatment Market by Application:
Cytomegalovirus Treatment Market by Distribution Channel:
Cytomegalovirus Treatment Market by Region:
Demand for cytomegalovirus treatment is predicted to increase at a CAGR of 6.1% from 2022 to 2028.
The global cytomegalovirus treatment market stands at a net worth US$ 228.8 Mn in 2022.
By 2028, the global cytomegalovirus treatment market is anticipated to attain a valuation of US$ 326 Mn.
Prime market players such as Chimerix Inc., Thermo Fisher Scientific, Abbot, Becton Dickinson and Company, Pfizer Inc., Merck & Company Inc., Mylan N.V., Johnson & Johnson, and Bio-Rad Laboratories Inc. have been profiled in this market survey.
At present, hospital pharmacies account for a dominant share of 46.8% in the global cytomegalovirus treatment industry.
1. Executive Summary
1.1. Market Overview
1.2. Market Analysis
1.3. FMI Analysis and Recommendations
1.4. Wheel of Fortune
2. Market Introduction
2.1. Market Taxonomy
2.2. Market Definition
3. Market Background
3.1. Market Overview
3.2. Macroeconomic Assumptions
3.3. Global Economic Outlook
4. Market Dynamics
4.1. Market Dynamics
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunity Analysis
4.1.4. Trends
5. Cytomegalovirus Treatment Market: Key Inclusions
5.1. Pipeline Analysis
5.2. Reimbursement Scenarios
5.3. Cytomegalovirus Treatment: Timeline
6. North America Cytomegalovirus Treatment Market Analysis 2013–2021 and Opportunity Assessment 2022–2028
6.1. Introduction
6.2. Historical Market Size (US$ Mn) Analysis By Country, 2013–2021
6.2.1. U.S.
6.2.2. Canada
6.3. Market Size (US$ Mn) Opportunity Assessment By Country, 2022–2028
6.4. Historical Market Size (US$ Mn) Trend Analysis By Drug Type, 2013–2021
6.4.1. Ganciclovir
6.4.2. Valganciclovir
6.4.3. Foscarnet
6.4.4. Cidofovir
6.4.5. Others
6.5. Market Size (US$ Mn) Opportunity Assessment By Drug Type, 2022–2028
6.6. Historical Market Size (US$ Mn) Trend Analysis By Application, 2013–2021
6.6.1. Stem Cell Transplantation
6.6.2. Organ Transplantation
6.6.3. Congenital CMV infection
6.6.4. Others
6.7. Market Size (US$ Mn) Opportunity Assessment By Application, 2022–2028
6.8. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013–2021
6.8.1. Hospital pharmacies
6.8.2. Retail Pharmacies
6.8.3. E-commerce
6.9. Market Size (US$ Mn) Opportunity Assessment By Distribution Channel, 2022–2028
6.10. Market Attractiveness Analysis
6.10.1. By Country
6.10.2. By Drug Type
6.10.3. By Application
6.10.4. By Distribution Channel
6.11. Drivers and Restraints – Impact Analysis
7. Western Europe Cytomegalovirus Treatment Market Analysis 2013–2021 and Opportunity Assessment 2022–2028
7.1. Introduction
7.2. Historical Market Size (US$ Mn) By Country, 2013–2021
7.2.1. Germany
7.2.2. France
7.2.3. U.K.
7.2.4. Spain
7.2.5. Italy
7.2.6. Rest of Western Europe
7.3. Market Size (US$ Mn) Opportunity Assessment By Country, 2022–2028
7.4. Historical Market Size (US$ Mn) Trend Analysis By Drug Type, 2013–2021
7.4.1. Ganciclovir
7.4.2. Valganciclovir
7.4.3. Foscarnet
7.4.4. Cidofovir
7.4.5. Others
7.5. Market Size (US$ Mn) Opportunity Assessment By Drug Type, 2022–2028
7.6. Historical Market Size (US$ Mn) Trend Analysis By Application, 2013–2021
7.6.1. Stem Cell Transplantation
7.6.2. Organ Transplantation
7.6.3. Congenital CMV infection
7.6.4. Others
7.7. Market Size (US$ Mn) Opportunity Assessment By Application, 2022–2028
7.8. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013–2021
7.8.1. Hospital pharmacies
7.8.2. Retail Pharmacies
7.8.3. E-commerce
7.9. Market Size (US$ Mn) Opportunity Assessment By Distribution Channel, 2022–2028
7.10. Market Attractiveness Analysis
7.10.1. By Country
7.10.2. By Drug Type
7.10.3. By Application
7.10.4. By Distribution Channel
7.11. Drivers and Restraints – Impact Analysis
8. Eastern Europe Cytomegalovirus Treatment Market Analysis 2013–2021 and Opportunity Assessment 2022–2028
8.1. Introduction
8.2. Historical Market Size (US$ Mn) By Country, 2013–2021
8.2.1. Russia
8.2.2. Poland
8.2.3. Rest of Eastern Europe
8.3. Market Size (US$ Mn) Opportunity Assessment By Country, 2022–2028
8.4. Historical Market Size (US$ Mn) Trend Analysis By Drug Type, 2013–2021
8.4.1. Ganciclovir
8.4.2. Valganciclovir
8.4.3. Foscarnet
8.4.4. Cidofovir
8.4.5. Others
8.5. Market Size (US$ Mn) Opportunity Assessment By Drug Type, 2022–2028
8.6. Historical Market Size (US$ Mn) Trend Analysis By Application, 2013–2021
8.6.1. Stem Cell Transplantation
8.6.2. Organ Transplantation
8.6.3. Congenital CMV infection
8.6.4. Others
8.7. Market Size (US$ Mn) Opportunity Assessment By Application, 2022–2028
8.8. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013–2021
8.8.1. Hospital pharmacies
8.8.2. Retail Pharmacies
8.8.3. E-commerce
8.9. Market Size (US$ Mn) Opportunity Assessment By Distribution Channel, 2022–2028
8.10. Market Attractiveness Analysis
8.10.1. By Country
8.10.2. By Drug Type
8.10.3. By Application
8.10.4. By Distribution Channel
8.11. Drivers and Restraints – Impact Analysis
9. Latin America Cytomegalovirus Treatment Market Analysis 2013–2021 and Opportunity Assessment 2022–2028
9.1. Introduction
9.2. Historical Market Size (US$ Mn) By Country, 2013–2021
9.2.1. Brazil
9.2.2. Mexico
9.2.3. Rest of Latin America
9.3. Market Size (US$ Mn) Opportunity Assessment By Country, 2022–2028
9.4. Historical Market Size (US$ Mn) Trend Analysis By Drug Type, 2013–2021
9.4.1. Ganciclovir
9.4.2. Valganciclovir
9.4.3. Foscarnet
9.4.4. Cidofovir
9.4.5. Others
9.5. Market Size (US$ Mn) Opportunity Assessment By Drug Type, 2022–2028
9.6. Historical Market Size (US$ Mn) Trend Analysis By Application, 2013–2021
9.6.1. Stem Cell Transplantation
9.6.2. Organ Transplantation
9.6.3. Congenital CMV infection
9.6.4. Others
9.7. Market Size (US$ Mn) Opportunity Assessment By Application, 2022–2028
9.8. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013–2021
9.8.1. Hospital pharmacies
9.8.2. Retail Pharmacies
9.8.3. E-commerce
9.9. Market Size (US$ Mn) Opportunity Assessment By Distribution Channel, 2022–2028
9.10. Market Attractiveness Analysis
9.10.1. By Country
9.10.2. By Drug Type
9.10.3. By Application
9.10.4. By Distribution Channel
9.11. Drivers and Restraints – Impact Analysis
10. Asia Pacific excluding China (APEC) Cytomegalovirus Treatment Market Analysis 2013–2021 and Opportunity Assessment 2022–2028
10.1. Introduction
10.2. Historical Market Size (US$ Mn) By Country, 2013–2021
10.2.1. India
10.2.2. Australia and New Zealand
10.2.3. Japan
10.2.4. Rest of APEJ
10.3. Market Size (US$ Mn) Opportunity Assessment By Country, 2022–2028
10.4. Historical Market Size (US$ Mn) Trend Analysis By Drug Type, 2013–2021
10.4.1. Ganciclovir
10.4.2. Valganciclovir
10.4.3. Foscarnet
10.4.4. Cidofovir
10.4.5. Others
10.5. Market Size (US$ Mn) Opportunity Assessment By Drug Type, 2022–2028
10.6. Historical Market Size (US$ Mn) Trend Analysis By Application, 2013–2021
10.6.1. Stem Cell Transplantation
10.6.2. Organ Transplantation
10.6.3. Congenital CMV infection
10.6.4. Others
10.7. Market Size (US$ Mn) Opportunity Assessment By Application, 2022–2028
10.8. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013–2021
10.8.1. Hospital pharmacies
10.8.2. Retail Pharmacies
10.8.3. E-commerce
10.9. Market Size (US$ Mn) Opportunity Assessment By Distribution Channel, 2022–2028
10.10. Market Attractiveness Analysis
10.10.1. By Country
10.10.2. By Drug Type
10.10.3. By Application
10.10.4. By Distribution Channel
10.11. Drivers and Restraints – Impact Analysis
11. China Cytomegalovirus Treatment Market Analysis 2013–2021 and Opportunity Assessment 2022–2028
11.1. Introduction
11.2. Historical Market Size (US$ Mn) Trend Analysis By Drug Type, 2013–2021
11.2.1. Ganciclovir
11.2.2. Valganciclovir
11.2.3. Foscarnet
11.2.4. Cidofovir
11.2.5. Others
11.3. Market Size (US$ Mn) Opportunity Assessment By Drug Type, 2022–2028
11.4. Historical Market Size (US$ Mn) Trend Analysis By Application, 2013–2021
11.4.1. Stem Cell Transplantation
11.4.2. Organ Transplantation
11.4.3. Congenital CMV infection
11.4.4. Others
11.5. Market Size (US$ Mn) Opportunity Assessment By Application, 2022–2028
11.6. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013–2021
11.6.1. Hospital pharmacies
11.6.2. Retail Pharmacies
11.6.3. E-commerce
11.7. Market Size (US$ Mn) Opportunity Assessment By Distribution Channel, 2022–2028
11.8. Market Attractiveness Analysis
11.8.1. By Drug Type
11.8.2. By Application
11.8.3. By Distribution Channel
11.9. Drivers and Restraints – Impact Analysis
12. MEA Cytomegalovirus Treatment Market Analysis 2013–2021 and Opportunity Assessment 2022–2028
12.1. Introduction
12.2. Historical Market Size (US$ Mn) By Country, 2013–2021
12.2.1. GCC Countries
12.2.2. South Africa
12.2.3. Rest of MEA
12.3. Market Size (US$ Mn) Opportunity Assessment By Country, 2022–2028
12.4. Historical Market Size (US$ Mn) Trend Analysis By Drug Type, 2013–2021
12.4.1. Ganciclovir
12.4.2. Valganciclovir
12.4.3. Foscarnet
12.4.4. Cidofovir
12.4.5. Others
12.5. Market Size (US$ Mn) Opportunity Assessment By Drug Type, 2022–2028
12.6. Historical Market Size (US$ Mn) Trend Analysis By Application, 2013–2021
12.6.1. Stem Cell Transplantation
12.6.2. Organ Transplantation
12.6.3. Congenital CMV infection
12.6.4. Others
12.7. Market Size (US$ Mn) Opportunity Assessment By Application, 2022–2028
12.8. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013–2021
12.8.1. Hospital pharmacies
12.8.2. Retail Pharmacies
12.8.3. E-commerce
12.9. Market Size (US$ Mn) Opportunity Assessment By Distribution Channel, 2022–2028
12.10. Market Attractiveness Analysis
12.10.1. By Country
12.10.2. By Drug Type
12.10.3. By Application
12.10.4. By Distribution Channel
12.11. Drivers and Restraints – Impact Analysis
13. Forecast Factors: Relevance and Impact
14. Competition Analysis
14.1. Competition Dashboard
14.2. Company Deep Dive
14.2.1. Merck & Co. Inc.,
14.2.1.1. Overview
14.2.1.2. Product and Application Portfolio
14.2.1.3. Analyst Commentary
14.2.1.4. Strategy
14.2.1.4.1. Marketing Strategy
14.2.1.4.2. Product Strategy
14.2.1.4.3. Channel Strategy
14.2.2. Mylan N.V.
14.2.3. Chimerix, Inc.,
14.2.4. Thermo Fisher Scientific
14.2.5. Abbott
14.2.6. Becton, Dickinson and Company,
14.2.7. Johnson & Johnson,
14.2.8. Bio-Rad Laboratories, Inc.,
14.2.9. F. Hoffmann-La Roche Ltd
14.2.10. Pfizer
15. Global Cytomegalovirus Treatment Market Analysis 2013–2021 and Opportunity Assessment 2022–2028, By Region
15.1. Introduction / Key Findings
15.2. Historical Market Size (US$ Mn) Trend Analysis By Region, 2013–2021
15.2.1. North America
15.2.2. Western Europe
15.2.3. Eastern Europe
15.2.4. Latin America
15.2.5. Asia Pacific excluding China
15.2.6. China
15.2.7. Middle East and Africa
15.3. Market Size (US$ Mn) Opportunity Assessment By Region, 2022–2028
15.4. Market Attractiveness Analysis By Region
16. Global Cytomegalovirus Treatment Market Analysis 2013–2021 and Opportunity Assessment 2022–2028, By Drug Type
16.1. Introduction
16.2. Historical Market Size (US$ Mn) and Trend Analysis By Drug Type, 2013–2021
16.2.1. Ganciclovir
16.2.2. Valganciclovir
16.2.3. Foscarnet
16.2.4. Cidofovir
16.2.5. Others
16.3. Market Size (US$ Mn) Opportunity Assessment By Drug Type, 2022–2028
16.4. Market Attractiveness Analysis By Drug Type
17. Global Cytomegalovirus Treatment Market Analysis 2013–2021 and Opportunity Assessment 2022–2028, By Application
17.1. Introduction
17.2. Historical Market Size (US$ Mn) Trend Analysis By Application, 2013–2021
17.2.1. Stem Cell Transplantation
17.2.2. Organ Transplantation
17.2.3. Congenital CMV infection
17.2.4. Others
17.3. Market Size (US$ Mn) Opportunity Assessment By Application, 2022–2028
17.4. Market Attractiveness Analysis By Application
18. Global Cytomegalovirus Treatment Market Analysis 2013–2021 and Opportunity Assessment 2022–2028, By Distribution Channel
18.1. Introduction
18.2. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013–2021
18.2.1. Hospital pharmacies
18.2.2. Retail Pharmacies
18.2.3. E-commerce
18.3. Market Size (US$ Mn) Opportunity Assessment By Distribution Channel, 2022–2028
18.4. Market Attractiveness Analysis By Distribution Channel
19. Global Cytomegalovirus Treatment Market Analysis 2013–2021 and Opportunity Assessment 2022–2028
19.1. Market Value Share Analysis
19.1.1. By Country
19.1.2. By Drug Type
19.1.3. By Application
19.1.4. By Distribution Channel
19.2. Y-o-Y Growth Analysis
19.2.1. By Country
19.2.2. By Drug Type
19.2.3. By Application
19.2.4. By Distribution Channel
19.3. Absolute $ Opportunity
20. Assumptions and Acronyms Used
21. Research Methodology
Explore Healthcare Insights
View Reports
Cytomegalovirus Treatment Market
